News Johnson & Johnson Swiss Exchange

Equities

JNJ

US4781601046

Market Closed - Swiss Exchange Other stock markets 11:36:39 2023-03-01 am EST			5-day change	1st Jan Change
500 ^CHF	+194.12%		-.--%	-.--%

05:15pm	J&J-backed Rapport Therapeutics shares debut nearly 6% higher	RE
03:06pm	J&J: FDA approves VELYS for knee arthroplasty	CF

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

J&J-backed Rapport Therapeutics shares debut nearly 6% higher	11:15am	RE
Johnson & Johnson : DePuy Synthes Receives 510(k) FDA Clearance of the VELYS™ Robotic-Assisted Solution for Use in Unicompartmental Knee Arthroplasty Procedures	09:58am	PU
J&J: FDA approves VELYS for knee arthroplasty	09:06am	CF
AbbVie's tight grip on Humira market raises concerns about biosimilars	06:00am	RE
J&J-backed Rapport Therapeutics raises $136 mln in US IPO	07:51pm	RE
Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	Jun. 06	MT
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	Jun. 05	AQ
J&J: applies to FDA for expanded indication for Prezcobix	Jun. 05	CF
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results	Jun. 04	BU
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab	Jun. 04
J&J: successful trial for Carvykti in multiple myeloma	Jun. 04	CF
J&J: promising trial for Tecvayli in multiple myeloma	Jun. 04	CF
Johnson & Johnson : showcases innovation and leadership in rheumatology at EULAR 2024 Congress	Jun. 04	PU
Johnson & Johnson Ordered to Pay $260 Million In Talc Powder Case	Jun. 04	MT
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors	Jun. 04	AQ
J&J must pay $260 million in latest talc trial, Oregon jury says	Jun. 03	RE
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses	Jun. 03	MT
Johnson & Johnson Announces Results from a Subgroup Analysis of the Phase 3 CARTITUDE-4 Study	Jun. 03	CI
Johnson & Johnson Announces Data from the Phase 3 PERSEUS Study	Jun. 03	CI
Johnson & Johnson Announces New Data from the Phase 2 PALOMA-2 Study Evaluating Subcutaneous (SC) Amivantamab Combined with Lazertinib as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer	Jun. 03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST